查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470873

患者異質骨移植/PDX 模型市場：按類型、腫瘤類型、應用和最終用戶 - 2024-2030 年全球預測

Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

患者來源的異質骨移植/PDX模型市場規模預計2023年為2.2226億美元，2024年達到2.5351億美元，2030年將成長至5.7499億美元，預計複合年成長率為14.54%。

患者來源的異種移植模型（PDX）是一種前沿的癌症研究模型，將人類腫瘤組織和細胞直接移植到免疫力缺乏或人源化小鼠體內，以在體內生長和維持患者的腫瘤，成為一種藥物開發工具。全球癌症發生率不斷上升，增加了對有效治療方法的需求，並增加了對研發活動的投資。然而，與獲取患者組織樣本相關的倫理和監管問題以及人類和小鼠之間的生理差異限制了患者來源的異種移植（PDX）模式的發展。此外，政府對癌症研究的資助增加以及分子​​表徵技術的進步預計將在未來創造利潤豐厚的機會。

主要市場統計
基準年[2023] 2.2226億美元
預測年份 [2024] 25351萬美元
預測年份 [2030] 57499萬美元
複合年成長率（%） 14.54%

小鼠模型廣泛用於腫瘤學中以開發新的療法。

小鼠模型是使用最廣泛的 PDX 模型，因為它們體積小、易於操作且在基因上與人類相似。這些模型對腫瘤生物學的理解和腫瘤學新治療方法的發展做出了重大貢獻。另一方面，大鼠模型由於其體積大以及在外科手術、影像診斷和採樣方面的優勢，已成為小鼠 PDX 模型的有價值的替代品。此外，大鼠在模擬某些人類癌症類型（例如神經膠質瘤和肉瘤）時表現出更多樣化的免疫反應和更高的保真度。

腫瘤類型：專注於婦科腫瘤模型，研究婦科癌症。

胃腸道 (GI) 腫瘤模型對於研究影響消化器官系統（例如大腸直腸癌、胃癌和胰腺癌）至關重要。這些模型可用於研究腫瘤發展和轉移的潛在機制以及評估潛在的治療方法。婦科腫瘤模型對於婦科癌症（包括卵巢、子宮內膜癌和子宮頸癌）的研究至關重要。血液腫瘤模型用於研究血液癌症，如白血病、淋巴瘤和多發性骨髓瘤。呼吸道腫瘤模型對於研究肺癌的病理和治療方法至關重要。泌尿系統腫瘤模型對於研究泌尿器官系統癌症（例如膀胱癌、腎臟癌和前列腺癌）非常重要，它可以讓研究人員了解疾病的發展並確定個人化的治療策略。

應用：在基礎癌症研究中擴大採用患者來源的異種移植（PDX）模型

患者來源的異質骨移植（PDX）模型在基礎癌症研究中非常有價值，因為它們忠實地模擬了腫瘤環境和患者異質性。生物標記分析對於識別預測和預後標記以指導個別患者的治療決策至關重要。 PDX 模型透過捕捉腫瘤生長和治療反應的分子變化來實現全面的生物標記開發。臨床前藥物開發在很大程度上依賴 PDX 模型來評估臨床實驗藥物的安全性、有效性和藥物動力學特性。 PDX模型概括了人類癌症的複雜性和多樣性，因此是進入臨床試驗前評估抗癌藥物的首選。

最終用戶：提高學術和研究機構中患者來源的異質骨移植的適用性

學術和研究機構主要促進癌症生物學、藥效測試和個人化醫療開發的研究。這些機構使用 PDX 模型來識別新的治療標靶並了解腫瘤進展的機制。委外研發機構(CRO) 使用 PDX 模型進行藥物發現和研發，為製藥和生物技術公司提供臨床前和臨床測試服務。 CRO 將這些模型應用於藥物開發的各個階段，包括標靶辨識/驗證、先導藥物最適化、藥物動力學/動態(PK/PD) 測試和毒性評估。製藥和生物技術公司正在採用 PDX 模型來支持其藥物發現管道並滿足個人化癌症治療的需求。

區域洞察

由於政府的支持措施以及促進該領域進步的各種研究機構的存在，美洲的 PDX 市場高度發展。此外，該地區的生物技術公司在為藥物發現和個人化醫療方法提供 PDX 服務方面具有巨大價值。在歐盟 (EU)，歐盟資助的計劃重點在於擴大成員國對 PDX 模型的使用。中東地區對 PDX 建模研究的興趣與日俱增，各組織紛紛採取舉措，為臨床前癌症模型開發開發專業知識和資源。在亞太地區，生物醫學研究的投入帶動了國內藥廠PDX模型研究的激增。亞太地區的政府框架也支持促進 PDX 模型研究的舉措，為患者來源的異質骨移植/PDX 模型市場開發潛在平台。

FPNV定位矩陣

FPNV定位矩陣對於評估患者來源的異質骨移植/PDX模型市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對患者異質骨移植/PDX 模型市場中供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.患者異質骨移植/PDX模型市場的市場規模和預測是多少？

2.在病患異質骨移植/PDX模型市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.人異質骨移植/PDX模型市場的技術趨勢與法規結構是什麼？

4.在病患異質骨移植/PDX模型市場中主要供應商的市場佔有率是多少？

5. 進入病人源性異質骨移植/PDX模型市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 個人化醫療需求不斷成長
      • 腫瘤學和臨床前開發
      • 為申請人準備臨床前計劃和文件提供政府計劃資助和服務
    • 抑制因素
      • 個性化PDX模型高成本
    • 機會
      • 對人性化 PDX 模型的需求不斷成長
      • 藥物研發的成長
    • 任務
      • 在癌症研究中道德使用動物的嚴格準則
  • 市場區隔分析
    • 類型：透過在腫瘤學中廣泛使用小鼠模型來開發新治療方法
    • 腫瘤類型：聚焦婦科腫瘤模型，研究婦科癌症
    • 應用：擴大病患來源的異種移植（PDX）模型在基礎癌症研究中的採用
    • 最終使用者：擴大學術研究機構中病患來源的異種移植的範圍
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章患者異質骨移植/PDX 模型市場：依類型

  • 小鼠模型
  • 大鼠模型

第 7 章按腫瘤類型分類的病人異質骨移植/PDX 模型市場

  • 胃腸道腫瘤模型
  • 婦科腫瘤模型
  • 血液腫瘤模型
  • 呼吸道腫瘤模型
  • 泌尿系統腫瘤模型

第8章患者異質骨移植/PDX 模型市場：依應用分類

  • 基礎癌症研究
  • 生物標記分析
  • 臨床前藥物開發

第 9 章 病患異質骨移植/PDX 模型市場：依最終使用者分類

  • 學術/研究機構
  • 合約調查機構
  • 製藥和生物技術公司

第10章 美洲病患異質骨移植/PDX模型市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太患者異質骨移植/PDX模型市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的病人異質骨移植/PDX模型市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Kiyatec 和 Xenostart 正式宣布達成合作協議，將使用 Kiyatec 的 3D 球體篩檢平台 Kiya-Predict 提供相關的體外療效資料並幫助降低藥物開發成本。
    • Soteria 和 Certis 合作使用 AI 平台和小鼠異種移植物生成藥物反應預測
    • Gem Pharmatech 與 Charles River Laboratories 簽署獨家協議，分銷下一代 NCG 產品組合
  • 戰略分析和建議

第14章競爭組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-FF1601152744

[197 Pages Report] The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 222.26 million in 2023 and expected to reach USD 253.51 million in 2024, at a CAGR 14.54% to reach USD 574.99 million by 2030.

A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.

KEY MARKET STATISTICS
Base Year [2023] USD 222.26 million
Estimated Year [2024] USD 253.51 million
Forecast Year [2030] USD 574.99 million
CAGR (%) 14.54%

Type: Extensive use of mouse models in oncology to develop novel therapeutics

Mice models are the most widely used PDX models due to their properties such as small size, ease of handling, and genetic similarity to humans. These models contribute significantly to understanding tumor biology and developing novel therapeutic approaches in oncology. On the other hand, rat models have emerged as a valuable alternative to mice PDX models due to their larger size, which benefits surgical procedures, imaging, and sampling. Additionally, rats exhibit more diverse immune responses and higher fidelity in modeling certain human cancer types, such as glioma and sarcoma.

Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers

Gastrointestinal (GI) tumor models are crucial to studying cancers that affect the digestive system, such as colorectal, gastric, and pancreatic cancer. These models aid in examining the underlying mechanisms of tumor development and metastasis and evaluating potential therapeutic options. Gynecological tumor models are essential for studying gynecological cancers, including ovarian, endometrial, and cervical cancer. Researchers employ hematological tumor models to study blood cancers, including leukemia, lymphoma, and multiple myeloma. Respiratory tumor models are vital for investigating lung cancer pathogenesis and treatment options. Urological tumor models, crucial for studying cancers of the urinary system such as bladder, kidney, and prostate cancer, aid researchers in comprehending disease development and identifying personalized treatment strategies.

Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research

Patient-derived xenograft (PDX) models are highly valuable in basic cancer research as they closely mimic the tumor environment and patient heterogeneity. Biomarker analysis is essential for identifying predictive or prognostic markers that guide treatment decisions for individual patients. PDX models enable comprehensive biomarker development by capturing molecular changes during tumor growth and therapy response. Preclinical drug development relies heavily on PDX models to assess investigational therapies' safety, efficacy, and pharmacokinetic properties. They are a preferred choice for evaluating anticancer agents before entering clinical trials, as PDX models replicate the complexity and diversity of human cancers.

End-User: Rising applicability of patient-derived xenografts in academic and research institutes

Academic and research institutions primarily facilitate the study of cancer biology, drug efficacy testing, and personalized medicine development. These institutions use PDX models to identify novel therapeutic targets and understand tumor progression mechanisms. Contract Research Organizations (CROs) offer preclinical and clinical trial services for pharmaceutical and biotechnology companies using PDX models for drug discovery and development. CROs apply these models in various stages of drug development, including target identification/validation, lead optimization, pharmacokinetics/pharmacodynamics (PK/PD) studies, and toxicity evaluation. Pharmaceutical and biotechnology companies employ PDX models to support their drug discovery pipelines and address the demand for personalized oncology treatments.

Regional Insights

The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region's investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Patient-Derived Xenograft/PDX Model Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.

Market Segmentation & Coverage

This research report categorizes the Patient-Derived Xenograft/PDX Model Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Mice Models
    • Rat Models
  • Tumor Type
    • Gastrointestinal Tumor Models
    • Gynecological Tumor Models
    • Hematological Tumor Models
    • Respiratory Tumor Models
    • Urological Tumor Models
  • Application
    • Basic Cancer Research
    • Biomarker Analysis
    • Preclinical Drug Development
  • End-User
    • Academic & Research Institutions
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Patient-Derived Xenograft/PDX Model Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Patient-Derived Xenograft/PDX Model Market?

3. What are the technology trends and regulatory frameworks in the Patient-Derived Xenograft/PDX Model Market?

4. What is the market share of the leading vendors in the Patient-Derived Xenograft/PDX Model Market?

5. Which modes and strategic moves are suitable for entering the Patient-Derived Xenograft/PDX Model Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for personalized medicine
      • 5.1.1.2. Oncology and preclinical development
      • 5.1.1.3. Government programs funding and services for applicants in the preparation of their preclinical programs and documentation
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of personalized PDX model
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising demand for humanized PDX Model
      • 5.1.3.2. Growth in pharma R&D
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent guidelines regarding the ethical use of animals in cancer research
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Extensive use of mouse models in oncology to develop novel therapeutics
    • 5.2.2. Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
    • 5.2.3. Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
    • 5.2.4. End-User: Rising applicability of patient-derived xenografts in academic and research institutes
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Patient-Derived Xenograft/PDX Model Market, by Type

  • 6.1. Introduction
  • 6.2. Mice Models
  • 6.3. Rat Models

7. Patient-Derived Xenograft/PDX Model Market, by Tumor Type

  • 7.1. Introduction
  • 7.2. Gastrointestinal Tumor Models
  • 7.3. Gynecological Tumor Models
  • 7.4. Hematological Tumor Models
  • 7.5. Respiratory Tumor Models
  • 7.6. Urological Tumor Models

8. Patient-Derived Xenograft/PDX Model Market, by Application

  • 8.1. Introduction
  • 8.2. Basic Cancer Research
  • 8.3. Biomarker Analysis
  • 8.4. Preclinical Drug Development

9. Patient-Derived Xenograft/PDX Model Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Contract Research Organizations
  • 9.4. Pharmaceutical & Biotechnology Companies

10. Americas Patient-Derived Xenograft/PDX Model Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Patient-Derived Xenograft/PDX Model Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Patient-Derived Xenograft/PDX Model Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Kiyatec and Xenostart Formally Announce a Collaborative Agreement to Help Reduce Drug Development Costs by Providing Correlative ex Vivo Efficacy Data Using Kiyatec's 3D Spheroid Screening Platform, Kiya-Predict
    • 13.3.2. Soteria, Certis Partner to Generate Drug Response Predictions Using AI Platform, Mouse Xenografts
    • 13.3.3. GemPharmatech and Charles River Laboratories Sign Exclusive Agreement to Distribute Next Generation NCG Portfolio
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET RESEARCH PROCESS
  • FIGURE 2. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET DYNAMICS
  • FIGURE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY MICE MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RAT MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GASTROINTESTINAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY GYNECOLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY HEMATOLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY RESPIRATORY TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY UROLOGICAL TUMOR MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BASIC CANCER RESEARCH, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY TUMOR TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR PATIENT-DERIVED XENOGRAFT/PDX MODEL MARKET SIZE, BY END-USER, 2024